

2X Oncology Inc. – a private spinout of Oncology Venture – to Present at Jefferies Global Healthcare Conference

Hoersholm, Denmark; May 31st, 2017 – Oncology Venture Sweden AB (OV:ST) announces that its spinout 2X Oncology, Inc., a company focused on developing targeted therapeutics to address significant unmet needs in women's cancer, will present at the upcoming Jefferies Global Healthcare Conference in New York City.

The presentation will be given by George O. Elston, chief executive officer of 2X Oncology, on Friday, June 9 at 10:00 am EDT. The presentation will be webcast live and archived for 90 days on the 2X Oncology website, 2xoncology.com, under the 'News' tab.

Mr. Elston will be joined by other members of the executive team for a breakout session immediately after the presentation, and for one-on-one meetings throughout the conference. Parties interested in meeting with 2X should contact their Jefferies representative or [Amy Raskopf](#) of 2X Oncology.

The 2X pipeline includes product candidates focused on breast, ovarian, and endometrial cancers and primary and secondary brain tumors. These programs have shown clinical efficacy and safety and are positioned to enter focused Phase 2 studies with data expected in 2018.

These targeted therapeutics leverage proprietary Drug Response Predictor (DRP™) companion diagnostic technology to address significant unmet needs in women's cancer. The DRP generates a precision mRNA-based companion diagnostic for each compound, enabling the identification of patients that are most likely to respond and benefit from treatment.

Based in Cambridge, MA (USA), 2X works in close collaboration with Oncology Venture and leverages OV's Danish registry of over 1,100 cancer patients for initial clinical studies.

DRP™ is a trademark of Medical Prognosis Institute A/S.

For further information about Oncology Venture, please contact:

Ulla Hald Buhl, COO and
Chief IR & Communications
Mobile: +45 2170 1049
uhb@oncologyventure.com

Or

Peter Buhl Jensen, CEO
Mobile: +45 21 60 89 22
E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use the Drug Response Predictor – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients' tumors' genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.